GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Ending Cash Position

Avicanna (TSX:AVCN) Ending Cash Position : C$0.45 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Avicanna Ending Cash Position?

Avicanna's Ending Cash Position for the quarter that ended in Dec. 2024 was C$0.45 Mil.

Avicanna's quarterly Ending Cash Position increased from Jun. 2024 (C$0.49 Mil) to Sep. 2024 (C$0.81 Mil) but then declined from Sep. 2024 (C$0.81 Mil) to Dec. 2024 (C$0.45 Mil).

Avicanna's annual Ending Cash Position declined from Dec. 2022 (C$1.19 Mil) to Dec. 2023 (C$0.48 Mil) and declined from Dec. 2023 (C$0.48 Mil) to Dec. 2024 (C$0.45 Mil).


Avicanna Ending Cash Position Historical Data

The historical data trend for Avicanna's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Ending Cash Position Chart

Avicanna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 1.27 0.03 1.19 0.48 0.45

Avicanna Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.85 0.49 0.81 0.45

Avicanna Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Avicanna's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.478+-0.03
=0.45

Avicanna's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.812+-0.364
=0.45


Avicanna Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Avicanna's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Avicanna Business Description

Traded in Other Exchanges
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.
Executives
Sheldon Inwentash 10% Security Holder
Threed Capital Inc. 10% Security Holder
Phillip Cardella Senior Officer
Aras Azadian Director, Senior Officer
Davender Sohi Senior Officer
David White Director
Kyle Lawrence Langstaff Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Chandra Panchal Director
Janet Giesselman Director

Avicanna Headlines

No Headlines